Переходьте в офлайн за допомогою програми Player FM !
Targeted therapies for lung cancer at TTLC 2024
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 25, 2024 14:05 ()
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 403982417 series 2424442
This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.
Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.
Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.
Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.
The post Targeted therapies for lung cancer at TTLC 2024 appeared first on VJOncology.
179 епізодів
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 25, 2024 14:05 ()
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 403982417 series 2424442
This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.
Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.
Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.
Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.
The post Targeted therapies for lung cancer at TTLC 2024 appeared first on VJOncology.
179 епізодів
Wszystkie odcinki
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.